Novo Nordisk's rare disease segment boosted by hemophilia treatments in Q3

Total sales of the Danish company’s treatments for rare diseases, which include bleeding disorders, grew to DKK 5.1bn (USD 679m) in the year’s third quarter.

Photo: Novo Nordisk / PR

Novo Nordisk’s third-quarter sales of Novoseven, a hemophilia treatment, surprised positively in a quarter where the Danish drugmaker’s revenues from its rare disease segment also increased.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs